Stock screenerAll disclosures →
EDGAR →
CYTK
Conviction 98HealthcareScan · Thu, Jun 25, 2026CYTK$80.79-0.50%
ResistanceSupportVol 14Insider sellCongress buyCongress sell3
5
Vol MA14 2.41M
Mar 26Apr 14May 1May 19Jun 8Jun 25
Price80.79
Change-0.50%
Gap-0.02%
Rel volume1.88×
Avg volume2.18M
Avg $ vol163.96M
SMA 2074.01
SMA 5072.10
SMA 20064.30
Price vs 50+12.06%
Price vs 200+25.65%
MA stackbullish
50/200 cross—
Supertrendup · 72.33
RSI (14)66
MACD hist0.99
MACD crossbull · 5d
Stoch %K / %D87 / 90
ADX (14)26
+DI / −DI30 / 12
RSI divergence—
MACD divergence—
ATR %+3.87%
ADR %4.15%
52w high81.20
52w low33.04
From 52w high-0.50%
Above 52w low+144.52%
New 52w highNo
SqueezeOff
Bollinger width24.39%
%B0.88
Donchian pos86.76%
Donchian high82.95
Donchian low66.63
AVWAP (52w high)81.39
vs AVWAP high-0.73%
AVWAP (52w low)60.40
vs AVWAP low+33.76%
OBV trendUp
Chaikin MF (20)-0.09
Today vs 20d1.88×
Avg vol (14d)2.41M
Avg vol (20d)2.18M
Avg $ vol (20d)163.96M
Market cap10.05B
RS 3m (vs SPY)+23.03%
RS 6m (vs SPY)+21.73%
RS line new highYes
Trend template8/8
Technical rank85.6
1 week+3.43%
1 month+5.90%
3 months+29.49%
6 months+23.16%
1 year+141.89%
YTD+30.88%
P/E-12.81
P/B-12.16
P/S114.19
P/FCF-18.80
EPS-6.54
Div yield—
ROE94.97%
ROA-61.64%
Debt/Eq-0.35
Current4.21
EV/EBITDA-16.96
Gross margin—
Net margin-891.60%
Rev growth376.56%
EPS growth-33.15%
Price target104.20
Target upside28.98%
Analyst ratingBuy
Institutional127.30%
Ent. value10.22B
Revenue19.36M
Net income-206.03M
Gross profit—
Free cash flow-534.82M
IndustryPHARMACEUTICAL PREPARATIONS
ExchangeNasdaq
Shares out124.43M
Employees673
ListedThu, Apr 29, 2004
Free float120.88M
Float %97.3%
Short interest15.5M
Days to cover8.6d
Short volume38.0%
Squeeze score64 / 100
Next earningsThu, Aug 6, 2026 (42d)
EPS forecast−$1.64 · 8 est
Last EPS vs est−$1.67 vs −$1.67
Last surprise0.0% beat
Setup gradeA+
Conviction98 / 100
Pattern quality—
Tech rank85.6 / 100
Group rank50 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance79.66
Support68.40
Days since event—
Candle confirm—
News sentiment—
Financials as of Tue, Mar 31, 2026 · quarterly.
Congress activity
Disclosed STOCK Act trades in CYTK · 3 recent
Insider activity
SEC Form 4 transactions in CYTK · 2 buys · 7 sells
| Insider | Side | Shares | Value | Traded | Filed |
|---|---|---|---|---|---|
Malik Fady Ibraham EVP Research & Development · Common Stock · 2026-06-09 | Sell | 3.5K | $238K | 2026-06-09 | 2026-06-09 |
Malik Fady Ibraham EVP Research & Development · Common Stock · 2026-06-09 | Exercise | 3.5K | $27K | 2026-06-09 | 2026-06-09 |
Malik Fady Ibraham EVP Research & Development · Non-Qualified Stock Option (Right to Buy) · 2026-06-09 | Exercise | 3.5K | $0 | 2026-06-09 | 2026-06-09 |
Callos Andrew EVP, Chief Commercial Officer · Non-Qualified Stock Option (Right to Buy) · 2026-06-01 | Exercise | 15K | $0 | 2026-06-01 | 2026-06-01 |
Kaye Edward M. MD Director · Common Stock · 2026-06-01 | Sell | 2.93K | $223K | 2026-06-01 | 2026-06-01 |
Callos Andrew EVP, Chief Commercial Officer · Common Stock · 2026-06-01 | Exercise | 15K | $349K | 2026-06-01 | 2026-06-01 |
Callos Andrew EVP, Chief Commercial Officer · Common Stock · 2026-06-01 | Sell | 15K | $1.1M | 2026-06-01 | 2026-06-01 |
PARSHALL B LYNNE Director · Common Stock · 2026-06-01 | Sell | 5K | $370K | 2026-06-01 | 2026-06-01 |
Blum Robert I President & CEO · Common Stock · 2026-05-27 | Sell | 7.5K | $579K | 2026-05-27 | 2026-05-28 |
Blum Robert I President & CEO · Common Stock · 2026-05-27 | Other | — | — | 2026-05-27 | 2026-05-28 |
SEC filings
EDGAR filings in CYTK · 2 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, cancel in one click.
Start free — 7-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.